Tesaro, Inc. (TSRO)

Oncology Corporate Profile

Stock Performance

155.7800
6.1100

HQ Location

1000 Winter Street, Suite 3300
Waltham, MA 02451

Company Description

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of patients with cancer. Our team of passionate associates develops and will commercialize safer and more effective supportive care agents and therapeutics.

Website: http://www.tesarobio.com

Brand Generic Indication
VARUBI™rolapitantVARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
niraparibPARP inhibitorBreast cancerIII
niraparibPARP inhibitorPlatinum-sensitive Ovarian cancerIII
TSR-011ALK inhibitorNon Small Cell Lung Cancer (NSCLC)I
TSR-042anti-PD-1 monoclonal antibodyVarious cancer typesI
TSR-011ALK inhibitorVarious cancer typesI

Source


http://www.tesarobio.com

Recent News Headlines

Lynparza Vs. Niraparib

3/15/2017 12:03 pm

Why Tesaro is Tanking

3/14/2017 08:00 pm

Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO

3/13/2017 03:01 pm

[GlobeNewswire] - NATIONAL HARBOR, Md., March 13, 2017-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results from the Phase 3 ENGOT-OV16/NOVA trial ...

TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women’s Cancer

3/12/2017 12:03 pm

[GlobeNewswire] - WALTHAM, Mass., March 12, 2017-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for Gynecologic Oncology Annual Meeting on ...

Blog Coverage CEL-SCI Provides Update on Late-stage Multikine Head and Neck Cancer Study

3/8/2017 01:01 pm

[Accesswire] - Upcoming AWS Coverage on TESARO Post-Earnings Results LONDON, UK / ACCESSWIRE / March 8, 2017 / Active Wall St. blog coverage looks at the headline from CEL-SCI Corp. (NYSE: CVM ) as the Company announced ...

TESARO, INC. Financials

3/4/2017 06:00 pm

Tesaro reports 4Q loss

2/28/2017 09:05 pm

Tesaro reports 4Q loss

2/28/2017 09:05 pm